Shopping Cart
Remove All
Your shopping cart is currently empty
Conatumumab (Synonyms: TRAIL-R2 mAb, AMG 655)
Catalog No. T76787 Copy Product Info
🥰Excellent
Conatumumab (AMG 655) is a monoclonal agonist antibody targeting human death receptor 5 [DR5, TRAILR2] with a dissociation constant (Kd) of 1 nM for long DR5 and 0.8 nM for short DR5. It induces apoptosis in various tumor types through caspase activation and can be used to study advanced solid tumors.
Conatumumab
Copy Product Info🥰Excellent
Catalog No. T76787
Synonyms TRAIL-R2 mAb, AMG 655
Conatumumab (AMG 655) is a monoclonal agonist antibody targeting human death receptor 5 [DR5, TRAILR2] with a dissociation constant (Kd) of 1 nM for long DR5 and 0.8 nM for short DR5. It induces apoptosis in various tumor types through caspase activation and can be used to study advanced solid tumors.
Conatumumab
Cas No. 896731-82-1
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $378 | In Stock | In Stock | |
| 5 mg | $955 | In Stock | In Stock | |
| 10 mg | $1,530 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:> 95%
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Conatumumab (AMG 655) is a monoclonal agonist antibody targeting human death receptor 5 [DR5, TRAILR2] with a dissociation constant (Kd) of 1 nM for long DR5 and 0.8 nM for short DR5. It induces apoptosis in various tumor types through caspase activation and can be used to study advanced solid tumors. |
| Targets&IC50 | DR5:<1 nM |
| In vitro | Activated caspase-3/7 in Colo205, H-2122, and MiaPaCa2 cells, conatumumab (0-10 μg/mL, 4 h) exhibited this effect[2]. Reducing the cell viability of sensitive tumor cell lines (Colo205, H-2122, and MiaPaCa2 cells), conatumumab (0-10 μg/mL, 24 h) demonstrated this activity[2]. |
| In vivo | In mice with Colo205, H2122, or MiaPaCa2/T2 xenograft tumors, Conatumumab (0-100 μg, intraperitoneal injection, twice a week) inhibited tumor growth[2]. Conatumumab (2.5 μg, i.p., 3 times a week) enhances the antitumor activity of chemotherapeutic drugs (CPT11) (80 mg/kg) in Colo 205 xenografts[2]. |
| Synonyms | TRAIL-R2 mAb, AMG 655 |
| Reactivity | Human |
| Verified Activity | Immobilized Cynomolgus DR5 Protein (ECD, His) at 2 μg/mL (30 μL/well) can bind Conatumumab. The EC50 is 111.9 ng/mL.  |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | TNFRSF10B/TRAILR2/CD262 |
| Molecular Weight | 145.44 kDa |
| Cas No. | 896731-82-1 |
| Isotype | Human IgG1 kappa |
| Recommended Isotype Control |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Keywords
Preview
Related Tags: buy Conatumumab | purchase Conatumumab | Conatumumab cost | order Conatumumab | Conatumumab in vivo | Conatumumab in vitro | Conatumumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.